Cargando…

(18)FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients

BACKGROUND: The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic properties of tumor cells using positron emission tom...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Cremoux, Patricia, Biard, Lucie, Poirot, Brigitte, Bertheau, Philippe, Teixeira, Luis, Lehmann-Che, Jacqueline, Bouhidel, Fatiha A., Merlet, Pascal, Espié, Marc, Resche-Rigon, Matthieu, Sotiriou, Christos, Groheux, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893244/ https://www.ncbi.nlm.nih.gov/pubmed/29662649 http://dx.doi.org/10.18632/oncotarget.24674

Ejemplares similares

(18)FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis
por: Groheux, David, et al.
Publicado: (2017)

HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
por: Groheux, D, et al.
Publicado: (2013)

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15
por: Lehmann-Che, Jacqueline, et al.
Publicado: (2013)

Cardiac sarcoidosis: A long term follow up study
por: Cacoub, Patrice, et al.
Publicado: (2020)

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen
por: Giacchetti, S, et al.
Publicado: (2014)

Prognostic Impact of (18)FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer
por: Groheux, David, et al.
Publicado: (2012)

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
por: Lehmann-Che, J, et al.
Publicado: (2011)

Severe infections in sarcoidosis: Incidence, predictors and long-term outcome in a cohort of 585 patients
por: Duréault, Amélie, et al.
Publicado: (2017)

Breast cancer: initial workup and staging with FDG PET/CT
por: Groheux, David, et al.
Publicado: (2021)

Evaluating mortality in intensive care units: contribution of competing risks analyses
por: Resche-Rigon, Matthieu, et al.
Publicado: (2006)

Early non-invasive ventilation for acute respiratory failure in immunocompromised patients (IVNIctus): study protocol for a multicenter randomized controlled trial
por: Lemiale, Virginie, et al.
Publicado: (2014)

Evaluation of the Propensity score methods for estimating marginal odds ratios in case of small sample size
por: Pirracchio, Romain, et al.
Publicado: (2012)

Stack or trash? Quality assessment of virtual slides
por: Ameisen, David, et al.
Publicado: (2013)

Towards better digital pathology workflows: programming libraries for high-speed sharpness assessment of Whole Slide Images
por: Ameisen, David, et al.
Publicado: (2014)

Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients
por: Allenbach, Yves, et al.
Publicado: (2020)

Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients
por: de Cremoux, Patricia, et al.
Publicado: (2011)

Do simple screening statistical tools help to detect reporting bias?
por: Pirracchio, Romain, et al.
Publicado: (2013)

Simple screening statistical tools to detect reporting bias: when should we ask for raw data?
por: Pirracchio, Romain, et al.
Publicado: (2013)

Prevention of cardiac surgery-associated acute kidney injury: a systematic review and meta-analysis of non-pharmacological interventions
por: Hariri, Geoffroy, et al.
Publicado: (2023)

Heckman imputation models for binary or continuous MNAR outcomes and MAR predictors
por: Galimard, Jacques-Emmanuel, et al.
Publicado: (2018)

Combining multiple imputation and meta-analysis with individual participant data
por: Burgess, Stephen, et al.
Publicado: (2013)

Luminal B breast tumors are not HER2 positive
por: Bhargava, Rohit, et al.
Publicado: (2008)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

Methodological management of end-of-life decision data in intensive care studies: A systematic review of 178 randomized control trials published in seven major journals
por: Kerever, Sébastien, et al.
Publicado: (2019)

Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans
por: Beaziz, Jessica, et al.
Publicado: (2021)

Behcet’s disease in budd-chiari syndrome
por: Desbois, Anne Claire, et al.
Publicado: (2014)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group
por: Hermine, Olivier, et al.
Publicado: (2022)

Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design
por: Porcher, Raphaël, et al.
Publicado: (2022)

Multiple imputation for cause-specific Cox models: Assessing methods for estimation and prediction
por: Bonneville, Edouard F, et al.
Publicado: (2022)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2021)

Luminal B breast tumors are not HER2 positive – authors' response
por: Tamimi, Rulla M, et al.
Publicado: (2008)

Large-scale analysis of cell-cell communication reveals angiogenin-dependent tumor progression in clear cell renal cell carcinoma
por: Massenet-Regad, Lucile, et al.
Publicado: (2023)

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
por: Cizkova, M, et al.
Publicado: (2013)

Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype
por: Yanagawa, Masumi, et al.
Publicado: (2012)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer
por: Cheng, Jingyi, et al.
Publicado: (2015)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7mgsd5d3vbks1v9pk0pffvv3nk